Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Marvel Biosciences's share price for the quarter that ended in Apr. 2024 was C$0.155. Marvel Biosciences's Shares Outstanding (EOP) for the quarter that ended in Apr. 2024 was 39.79 Mil. Therefore, Marvel Biosciences's market cap for the quarter that ended in Apr. 2024 was C$6.17 Mil.
Marvel Biosciences's quarterly market cap
increased
from Oct. 2023 (C$2.79 Mil) to Jan. 2024 (C$4.18 Mil) and
increased
from Jan. 2024 (C$4.18 Mil) to Apr. 2024 (C$6.17 Mil).
Marvel Biosciences's annual market cap
declined
from Jul. 2021 (C$7.82 Mil) to Jul. 2022 (C$3.15 Mil) but then
increased
from Jul. 2022 (C$3.15 Mil) to Jul. 2023 (C$3.18 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Marvel Biosciences's Enterprise Value for Today is C$5.66 Mil.
Marvel Biosciences Market Cap Historical Data
The historical data trend for Marvel Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Marvel Biosciences's Market Cap
For the Biotechnology subindustry, Marvel Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marvel Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Marvel Biosciences's Market Cap falls into.
Marvel Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Marvel Biosciences's Market Cap for the fiscal year that ended in Jul. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marvel Biosciences (TSXV:MRVL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Marvel Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Marvel Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Marvel Biosciences (TSXV:MRVL) Business Description
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:MRVL has been successfully added to your 